Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the lowest possible dose of GnRHa should be used. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study t...

Aim. To determine if hormonal treatment induces apoptosis in uterine fibroids. Methods. Immunohistochemical examination of fibroid tissue, using avidin-biotin complex and cleaved caspase-3 antibody for detecting apoptosis, was performed in premenopausal women who underwent 12-week treatment with oral SPRM (6 patients with 5 mg and 5 patients with 10 mg of ulipristal acetate per day) or gonadoli...

We studied 98 in-vitro fertilization (IVF) patients with a high basal follicle stimulating hormone (FSH; >6.5 IU/l) concentration on day 3 who were treated with a low dose gonadotrophin-releasing hormone agonist (GnRHa) protocol and who had received in the previous 6 months a long protocol with GnRHa in a depot formula. The evaluation was made using the previous IVF cycle of the same patient as...

background: endometriosis is a common gynecological problem associated with chronic pelvic pain. objective: to evaluate the effectiveness of current hormonal treatments of endometriosis associated pain. materials and methods: randomized controlled studies identified from databases of medline and cochrane systemic review groups were pooled. 7 rcts were recruited for evaluation in this review. da...

Several strategies can be applied to optimize GH treatment in GH-deficient (GHD) children during puberty (1). In a recent issue of JCEM, Mericq et al. (2) reported their results of a prospective, randomized trial on the effect of GH alone or in combination with GnRH agonist (GnRHa) in pubertal GHD patients. They concluded that delaying puberty by GnRHa led to a near final height (FH) sd score o...

Since the pioneering days of in vitro fertilization, hCG has been the gold standard to induce final follicular maturation. We herein reviewed different pharmaceutical options for triggering of final oocyte maturation in ART. The new upcoming agent seems to be GnRHa with its potential advantages over hCG trigger. GnRHa triggering elicits a surge of gonadotropins resembling the natural midcycle s...

OBJECTIVE Gonadotropin-Releasing Hormone agonists (GnRHa) are used to improve the final adult height in short stature children. There are limited studies which address the potential side effect of these agents: excessive weight gain. We have followed girls with rapidly progressive puberty receiving GnRHa and results were focused on the effect of treatment on final height, weight and body mass i...

Regarding adjuvant endocrine therapy for premenopausal patients with endocrine sensitive disease, the AGO recommendations have not changed substantially in 2011. Assessment of the menopausal status is best done by menstruation history and follicle-stimulating hormone (FSH) and estradiol (E2) measurements. Low anti-muellerian hormone (AMH) levels seem to be indicative for reduced ovarian reserve...

Fluid and solute transport across the epithelium of the male excurrent duct is important for sperm maturation and storage. Aquaporin 9 (AQP9), which allows permeation of water and neutral solutes, is abundant throughout the male reproductive tract, where it is expressed at the apical membrane of rat epididymal principal cells as early as at 1 week of age. We evaluated the effect of neonatal exp...

The histrelin implant has emerged as a therapeutic option for the treatment of central precocious puberty that has been favorably received by patients and providers. Inserted subcutaneously, the 50-mg implant provides continuous release of the potent gonadotropin-releasing hormone analog (GnRHa) histrelin. Profound suppression of the hypothalamic-pituitary-gonadal (HPG) axis occurs within 1 mon...